Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 412
- Registration Number
- NCT03969004
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
🇪🇸Hospital Universitario Virgen Macarena-merge, Sevilla, Spain
🇫🇷Hospital Saint-Louis - APHP, Paris Cedex 10, France
A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 259
- Registration Number
- NCT03956550
- Locations
- 🇺🇦
Regeneron Study Site, Kyiv, Ukraine
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT03949673
- Locations
- 🇵🇱
Regeneron Recruting SIte, Bialystok, Poland
🇬🇧Regeneron Research Site, Liverpool, United Kingdom
Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03946748
- Locations
- 🇬🇧
Regeneron Study Site, Airdrie, Lanarkshire, United Kingdom
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 3930
- Registration Number
- NCT03936335
- Locations
- 🇺🇸
Regeneron Research Site, Boston, Massachusetts, United States
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT03916627
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT03889912
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸Rochester Dermatologic Surgery, Victor, New York, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 576
- Registration Number
- NCT03888105
- Locations
- 🇺🇸
Tufts Cancer Center, Boston, Massachusetts, United States
🇨🇳Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Wuhan Hubei Province, China
🇨🇳Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT03838731
- Locations
- 🇫🇷
Regeneron Research Site, Strasbourg, France
CemiplimAb Survivorship Epidemiology
- Conditions
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT03836105
- Locations
- 🇺🇸
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
🇺🇸Harbor-UCLA/LA Biomedical Research Institute, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States